

FIG. 2A

Human G Protein Coupled Receptor Family
(Receptors known as of January, 1999)

CLASS	LIGAND	NUMBER	TISSUE	PHYSIOLOGY	THERAPEUTICS
Class I	Rhodopsin like				
	•Amine				
	•Acetylcholine (muscarinic & nicotinic)	5	Brain, Nerves, Heart	Neurotransmitter	Acuity, Alzheimer's
	•Adrenoceptors				
	•Alpha Adrenoceptors	6	Brain, Kidney, Lung	Gluconeogenesis	Diabetes, Cardiovascular
	•Beta Adrenoceptors	3	Kidney, Heart	Muscle Contraction	Cardiovascular, Respiratory
	•Dopamine	5	Brain, Kidney, GI	Neurotransmitter	Cardiovascular, Parkinson's
	•Histamine	2	Vascular, Heart, Brain	Vascular Permeability	Anti-inflammatory, Ulcers
	•Serotonin (5-HT)	16	Most Tissues	Neurotransmitter	Depression, Insomnia, Analgesic
	•Peptide				
	•Angiotensin	2	Vascular, Liver, Kidney	Vasoconstriction	Cardiovascular, Endocrine
	•Bradykinin	1	Liver, Blood	Vasodilation,	Anti-inflammatory, Asthma
	•C5a anaphylatoxin	1	Blood	Immune System	Anti-inflammatory
	•Fmet-leu-phe	3	Blood	Chemoattractant	Anti-inflammatory
	•Interleukin-8	1	Blood	Chemoattractant	Anti-inflammatory
	•Chemokine	6	Blood	Chemoattractant	Anti-inflammatory
	•Orexin	2	Brain	Fat Metabolism	Obesity
	•Nociceptin	1	Brain	Bronchodilator, Pain	Airway Diseases, Anesthetic
	•CCK (Gastrin)	2	Gastrointestinal	Motility, Fat Absorption	Gastrointestinal, Obesity, Parkinson's
	•Endothelin	2	Heart, Bronchus, Brain	Muscle Contraction	Cardiovascular, Respiratory
	•Melanocortin	5	Kidney, Brain	Metabolic Regulation	Anti-inflammatory, Analgesics
	•Neuropeptide Y	5	Nerves, Intestine, Blood	Neurotransmitter	Behavior, Memory, Cardiovascular
	•Neurotensin	1	Brain,	CNS	Cardiovascular, Analgesic
	•Opioid	3	Brain,	CNS	Depression, Analgesic
	•Somatostatin	5	Brain, Gastrointestinal	Neurotransmitter	Oncology, Alzheimer's



FIG. 2B

•Tachykinin (Substance P, NKA ₁)	3	Brain Nerves	Neurohormone	Depression, Analgesic
•Thrombin	3	Platelets, Blood Vessels	Coagulation	Anti-coagulant / Anti-inflammatory
•Vasopressin-like	4	Arteries, Heart, Bladder	Water Balance	Anti-diuretic, Diabetic Complications
•Galanin	1	Brain, Pancreas	Neurotransmitter	Analgesics, Alzheimer's
•Hormone protein				
•Follicle stimulating hormone	1	Ovary, Testis	Endocrine	Infertility
•Lutropin-choriogonadotropic	1	Ovary, Testis	Endocrine	Infertility
•Thyrotropin	1	Thyroid	Endocrine	Thyroidism, Metabolism
•(Rhod)opsin				
•Opsin	5	Eye	Photoreception	Ophthalmic Diseases
•Olfactory	4 (~1000)	Nose	Smell	Olfactory Diseases
•Prostanoid				
•Prostaglandin	5	Arterial, Gastrointestinal	Vasodilation, Pain	Cardiovascular, Analgesic
•Lysophosphatidic Acid	2	Vessels, Heart, Lung	Inflammation	Cancer, Anti-inflammatory
•Sphingosine-1-phosphate	2	Most Cells	Cell proliferation	Cancer
•Leukotriene	1	White Blood Cells, Bronchus	Inflammation	Asthma, Rheumatoid Arthritis
•Prostacyclin	1	Arterial, Gastrointestinal	Platelet Regulation	Cardiovascular
•Thromboxane	1	Arterial, Bronchus	Vasoconstriction	Cardiovascular, Respiratory
•Nucleotide-like				
•Adenosine	4	Vascular, Bronchus	Multiple Effects	Cardiovascular, Respiratory
•Purinocceptors	4	Vascular, Platelets	Relaxes Muscle	Cardiovascular, Respiratory
•Cannabis	2	Brain	Sensory Perception	Analgesics, Memory
•Platelet activating factor	1	Most Peripheral Tissues	Inflammation	Anti-inflammatory, Anti-asthmatic
•Gonadotropin-releasing hormone like				
•Gonadotropin-releasing hormone	1	Reproductive Organs, Pituitary	Reproduction	Prostate Cancer, Endometriosis
•Thyrotropin-releasing hormone	1	Pituitary, Brain	Thyroid Regulation	Metabolic Regulation
•Growth hormone-inhibiting factor	1	Gastrointestinal	Neuroendocrine	Oncology, Alzheimer's
•Melatonin	1	Brain, Eye, Pituitary	Neuroendocrine	Regulation of Circadian Cycle

FIG. 2C

●Class II				
Secretin like				
●Secretin	1	Gastrointestinal, Heart	Digestion	Obesity, Gastrointestinal Osteoporosis Stress, Mood, Obesity
●Calcitonin	1	Bone, Brain	Calcium Resorption	
●Corticotropin releasing factor/urocortin	1	Adrenal, Vascular, Brain	Neuroendocrine	
●Gastric inhibitory peptide (GIP)	1	Adrenals, Fat Cells	Sugar/Fat Metabolism	Diabetes, Obesity Cardiovascular Cardiovascular, Diabetes, Obesity Growth Regulation
●Glucagon	1	Liver, Fat Cells, Heart	Gluconeogenesis	
●Glucagon-like Peptide 1 (GLP-1)	1	Pancreas, Stomach, Lung	Gluconeogenesis	
●Growth hormone-releasing hormone	1	Brain	Neuroendocrine	
●Parathyroid hormone	1	Bone, Kidney	Calcium Regulation	
●PACAP	1	Brain, Pancreas, Adrenals	Metabolism	Osteoporosis Metabolic Regulation
●Vasoactive intestinal polypeptide (VIP)	1	Gastrointestinal	Motility	Gastrointestinal
●Class III				
●Metabotropic Glutamate	7	Brain	Sensory Perception	Hearing, Vision Mood Disorders Cataracts, GI Tumors
●GABA _B	1	Brain	Neurotransmitter	
●Extracellular Calcium Sensing	1	Parathyroid, Kidney, GI Tract	Calcium Regulation	

FIG. 3A

G protein-coupled receptors:

(Division into Class A

Or Class B)

1. **A1 adenosine receptor [Homo sapiens].** ACCESSION AAB25533
NPIVYAF RIQKFRVTFL KIWNDFHRCQ PAPPIDEDLP EERPDD
Class A
2. **adrenergic, alpha -1B-, receptor [Homo sapiens].** ACCESSION NP_000670
npiiypc sskefkrafv rilgcqcrgr grmmrrr lggcaytyrp wtrggslers qsrkdsldds gscslgsqrt lpsaspspgy
lrggappve lcafpewkap gallspape ppgrgrhds gplftfklit epespgtdgg asnggceaaa dvangqpgfk
snmplapggf
Class A
3. **adrenergic receptor alpha-2A [Homo sapiens].** ACCESSION AAG00447
npviytifn hdfirafkki lergdrkriv
Class A
4. **alpha-2B-adrenergic receptor - human.** ACCESSION A37223
npviytifn qdfirafiri lcrpwtqtaw
Class A
5. **alpha-2C-adrenergic receptor - human.** ACCESSION A31237
npviyvtfn qdfirpsfkhi lfrmrgrfr q
Class A
6. **beta-1-adrenergic receptor [Homo sapiens].** ACCESSION NP_000675
npiiycrs pdfirafqgl lccarraarr rhatgdrpr asgclarpgp ppspgaasdd ddddvvgatp parllepwag
cnggaaadsd ssldepcrpg faseskv
Class A
7. **beta-2 adrenergic receptor.** ACCESSION P07550
npliyersp dfirafqell clrrsslkay gngyssngnt 361 geqsgyhveq ekenklced lpgtedfvgh qgtvpsdnid
sqgrncstnd sll
Class A
8. **dopamine receptor D1 [Homo sapiens].** ACCESSION NP_000785
npii yafnadrka fstllgcyl cpatnaiet vsinnngaam fsshheprgs iskecnlyl iphavgsed lkkeeaagia
rpleklspal svldytdv slekiqpitq ngqhpt
Class A
9. **D(2) dopamine receptor.** ACCESSION P14416
npiiyttfn iefirafiki lhc
Class A

FIG. 3B

10. **d3 dopamine receptor - human.** ACCESSION G01977
np viyttfnief rkafkils
Class A
11. **dopamine receptor D4 - human.** ACCESSION DYHUD4
npviyvtv fnaefrnvfr kalracc
Class A
12. **dopamine receptor D5 - human.** ACCESSION DYHUD5
npviya fnadfqqvfa qlgcsfhfcs rtpvetvnis nelisynqdi vfhkeiaaay ihmmpnavtp gnrevdndee
egpfdrmfqi yqtspdgdpv aesvweldec geisldkitp fipngfh
Class A
13. **muscarinic acetylcholine receptor M1 [Homo sapiens].** ACCESSION NP_000729
nmpcyal cnkafrdfr lllcrwdkr rwrkipkrpg svhrtpsrgc
Class A
14. **muscarinic acetylcholine receptor M2 [Homo sapiens].** ACCESSION NP_000730
npacy alcnatfkkt fkhlimchyk nigatr
Class A
15. **muscarinic acetylcholine receptor M3 [Homo sapiens].** ACCESSION NP_000731
n pvcyalcnkt frttfkmlll cqedkkkrrk qqyqqrsqvi fhkrapeqal
Class A
16. **muscarinic acetylcholine receptor M4 [Homo sapiens].** ACCESSION NP_000732
npa cyalcnatfk ktfrhllecq yrnigtar
Class A
17. **m5 muscarinic receptor. locus HUMACHRM** ACCESSION AAA51569
npicyalcnr tfrktfkmll lcrwkkkkve eklywqgnsk lp
Class A
18. **5-hydroxytryptamine (serotonin) receptor 1A [Homo sapiens].** ACCESSION BAA90449
npviy ayfnkdfqna fkkiikckf
Class A
19. **5-hydroxytryptamine (serotonin) receptor 1B [Homo sapiens].** ACCESSION BAA94455
npiiyt msnedfkqaf hklirfkcts
Class A
20. **5-hydroxytryptamine (serotonin) receptor 1E [Homo sapiens].** ACCESSION BAA94458
n pllytsfnd fklafklir cre
Class A

FIG. 3C

21. **OLFACTORY RECEPTOR 6A1.** ACCESSION O95222
npiiyclmq evkralccil hlyqhqpdpd kkgsmv
Class A
22. **OLFACTORY RECEPTOR 2C1.** ACCESSION O95371
npliy tlnmevkga lrrllgkgre vg
Class A
23. **angiotensin receptor 1 [Homo sapiens].** ACCESSION NP_033611
npl fyglgkfkf ryflqllyi ppkakshnl sfkmsflsy psdnvssstk kpapefeve
Class B
24. **angiotensin receptor 2 [Homo sapiens].** ACCESSION NP_000677
npflycf vgnrfqqlr svfrvpitwl qgkresmscr kssslremet fvs
Class B
25. **interleukin 8 receptor beta (CXCR2) [Homo sapiens].** ACCESSION NM_001557
NPLIYAFIGQKFRHGLLKILAIHGLISKDSLPKDSRPSFVGSSSGHTSTTL
Class B
26. **cx3c chemokine receptor 1 (cx3cr1) (fractalkine receptor)**
ACCESSION P49238
np liyafagekf rrylyhlygk clavlgrsv hvdfsssesq rsrhgsvlss nftyhtsdgd allll
Class B
27. **neurotensin receptor - human.** ACCESSION S29506
n pilynlvsan frhiflatla clcpvwmtt krpafsrkad svssnhflss natretly
Class B
28. **SUBSTANCE-P RECEPTOR (SPR) (NK-1 RECEPTOR) (NK-1R).** ACCESSION P25103
npiiyccldn rfrlgfkfahf rccpfisagd yeglemkstr yltqgsvyk vsrlettistvvgaheeepe dgpkatpssl
dltsncssrs dskmtesfs fssnvl
Class B
29. **vasopressin receptor type 2 [Homo sapiens].** ACCESSION AAD16444
npwiyasfss svsselsll ccargtrpps lgpqdescft assslakdts s
Class B
30. **thyrotropin-releasing hormone receptor - human.** ACCESSION JN0708
npviy nlmsqkfraa frklcnckqk ptekpanysv alnysvikes dhfstelddi tvtdfylsat kvsfddtela sevsfsqs
Class B

FIG. 3D

31. **oxytocin receptor - human. ACCESSION A55493**
 npwiym lftghlfhel vqrfccsas ylkgrlget saskksnsss fvlsrsss q rscsqpsta
Class B

32. **neuromedin U receptor [Homo sapiens]. ACCESSION AAG24793**
 npvlyslmssrfretfgealclgacchrlprhsshslsrmittgstlcvdvgslgswvhplagndgpeaqgetdps
Class B

33. **gastrin receptor. ACCESSION AAC37528**
 nplvy cfmhrrfqa cletcarcep rpprarpral pdedpptpsi aslsrlsytt lsfllpgg
Class B

34. **galanin receptor 3 [Homo sapiens]. ACCESSION 10879541**
 nplv yalasrhfra rfrlwpcgr rrrhrarral rrvrpassgp pgcpgdarps grllagggqg pepregpvhg geaargpe
Class A

35. **edg-1 - human. ACCESSION A35300**
 npiiy tltnkemrra firimscecke psgdsagkfk rpiiagmefs rsksdnsshp 361 qkdegdnpet imssgnvnss s
Class A

36. **central cannabinoid receptor [Homo sapiens]. ACCESSION NP_057167**
 npiiyalr skdlrhafsr mfpscegtaq pldnsmgdsd clkhannaa svhraesci kstvkiakvt msvstdtsae al
Class A

37. **delta opioid receptor - human. ACCESSION I38532**
 npvlyaf ldenfkrcfr qlcrkpcgrp dpssfsrpre atarervtac tpsdgp gggr aa
Class A

38. **proteinase activated receptor 2 (PAR-2) human. ACCESSION P55085**
 dpfvyvfvshdfrdhaknallcrsvrtvkqm qvsltskkhsrksssyssssttvktsy
Class A

39. **vasopressive intestinal peptide receptor (VIPR) rat. ACCESSION NM_012685**
 NGEVQAELRRKWRRWHLQGVLGWSSKSQHPWGGSN GATCSTQVSM LTRVSPSARR
 SSSFQA EVSLV
Class B

FIG. 4A

The mutated amino acid at the second position of the DRY motif is underlined.

VASOPRESSIN V2 RECEPTOR - (Human)
accession P30518

R137H

```

1  MLMASTTSASV PGHPSLPSLP SNSSQERPLD TRDPLLARAE LALLSIVFVA VALSNGLVLA
61  ALARRGRRGH WAPIHVFIGH LCLADLAVAL FQVLPQLAWK ATDRFRGPDA LCRAVKYLQM
121 VGMYASSYMI LAMTLDHHRA ICRPMLAYRH GSGAHWNRPV LVAWAFSLLL SLPQLFIFAQ
181 RNVEGGSGVT DCWACFAEPW GRRTYVTWIA LMVFVAPTLG IAACQVLIFR EIHASLVPGP
241 SERPGGRRRG RRTGSPGEGA HVSAAVAKTV RMTLVIVVVY VLCWAPFFLV QLWAAWDPEA
301 PLEGAPFVLL MLLASLNSCT NPWIYASFSS SVSSELRSLL CCARGRTPPS LGPQDESCTT
361 ASSSLAKDTS S

```

(SEQ ID NO:40)

ALPHA-1B ADRENERGIC RECEPTOR (ALPHA 1B-ADRENOCEPTOR).
(Golden hamster)

ACCESSION P18841

R143E

```

1  MNPDLDTGHN TSAPAQWGEL KDANFTGPNQ TSSNSTLPQL DVTRAISVGL VLGAFILFAI
61  VGNILVILSV ACNRHLRTPT NYFIVNLAIA DLLLSFTVLP FSATLEVLGY WVLGRIFCDI
121 WAAVDVLCCT ASILSLCAIS IDEYIGVRYS LQYPTLVTRR KAILALLSVW VLSTVISIGP
181 LLGWKEPAPN DDKECGVTEE PFYALFSSLG SFYIPLAVIL VMYCRVYIVA KRTTKNLEAG
241 VMKEMSNSKE LTLRIHSKNF HEDTLSSTKA KGHNPRSSIA VKLFKFSREK KAAKTLGIVV
301 GMFILCWLPF FIALPLGSLF STLKPPDAVF KVVFWLGYFN SCLNPIIYPC SSKEFKRAFM
361 RILGCQCRSG RRRRRRRRLG ACAYTYRPWT RGGSLERSQS RKDSLDDSGS CMSGSQRTLP
421 SASPSPGYLG RGAQPPELC AYPEWKSGAL LSLPEPPGRR GRLDSGPLFT FKLLGEPESP
481 GTEGDASNGG CDATTDLANG QPGFKSNMPL APGHF

```

(SEQ ID NO:41)

R143A

```

1  MNPDLDTGHN TSAPAQWGEL KDANFTGPNQ TSSNSTLPQL DVTRAISVGL VLGAFILFAI
61  VGNILVILSV ACNRHLRTPT NYFIVNLAIA DLLLSFTVLP FSATLEVLGY WVLGRIFCDI
121 WAAVDVLCCT ASILSLCAIS IDAYIGVRYS LQYPTLVTRR KAILALLSVW VLSTVISIGP
181 LLGWKEPAPN DDKECGVTEE PFYALFSSLG SFYIPLAVIL VMYCRVYIVA KRTTKNLEAG
241 VMKEMSNSKE LTLRIHSKNF HEDTLSSTKA KGHNPRSSIA VKLFKFSREK KAAKTLGIVV
301 GMFILCWLPF FIALPLGSLF STLKPPDAVF KVVFWLGYFN SCLNPIIYPC SSKEFKRAFM
361 RILGCQCRSG RRRRRRRRLG ACAYTYRPWT RGGSLERSQS RKDSLDDSGS CMSGSQRTLP
421 SASPSPGYLG RGAQPPELC AYPEWKSGAL LSLPEPPGRR GRLDSGPLFT FKLLGEPESP
481 GTEGDASNGG CDATTDLANG QPGFKSNMPL APGHF

```

(SEQ ID NO:42)

FIG. 4B

R143H

1 MNPDLDTGHN TSAPAQWGEL KDANFTGPNQ TSSNSTLPQL DVTRAI SVGL VLGAFILFAI
 61 VGNILVILSV ACNRHLRTPT NYFIVNLAIA DLLLSFTVLP FSATLEVLGY WVLGRIFCDI
 121 WAAVDVLCCT ASILSLCAIS ID^HYIGVRYS LQYPTLVTRR KAILALLSVW VLSTVISIGP
 181 LLGWKEPAPN DDKECGVTEE PFYALFSSLG SFYIPLAVIL VMYCRVYIVA KRTTKNLEAG
 241 VMKEMSNSKE LTLRIHKNF HEDTLSSTKA KGHNPRSSIA VKLFKFSREK KAAKTLGIVV
 301 GMFILCWLPF FIALPLGSLF STLKPPDAVF KVVFWLGYFN SCLNPIIYPC SSKEFKRAFM
 361 RILGCQCRSG RRRRRRRRLG ACAYTYRPWT RGGSLERSQS RKDSLDDSGS CMSGSQRTLP
 421 SASPSPGYLG RGAQPPELC AYPEWKSGAL LSLPEPPGRR GRLD SGPLFT FKLLGEPESP
 481 GTEGDASNGG CDATTDLANG QPGFKSNMPL APGHF

(SEQ ID NO:43)

R143N

1 MNPDLDTGHN TSAPAQWGEL KDANFTGPNQ TSSNSTLPQL DVTRAI SVGL VLGAFILFAI
 61 VGNILVILSV ACNRHLRTPT NYFIVNLAIA DLLLSFTVLP FSATLEVLGY WVLGRIFCDI
 121 WAAVDVLCCT ASILSLCAIS ID^NYIGVRYS LQYPTLVTRR KAILALLSVW VLSTVISIGP
 181 LLGWKEPAPN DDKECGVTEE PFYALFSSLG SFYIPLAVIL VMYCRVYIVA KRTTKNLEAG
 241 VMKEMSNSKE LTLRIHKNF HEDTLSSTKA KGHNPRSSIA VKLFKFSREK KAAKTLGIVV
 301 GMFILCWLPF FIALPLGSLF STLKPPDAVF KVVFWLGYFN SCLNPIIYPC SSKEFKRAFM
 361 RILGCQCRSG RRRRRRRRLG ACAYTYRPWT RGGSLERSQS RKDSLDDSGS CMSGSQRTLP
 421 SASPSPGYLG RGAQPPELC AYPEWKSGAL LSLPEPPGRR GRLD SGPLFT FKLLGEPESP
 481 GTEGDASNGG CDATTDLANG QPGFKSNMPL APGHF

(SEQ ID NO:44)

FIG. 4C

Angiotensin II Receptor, Type 1 (AT1A) [Rattus norvegicus].
ACCESSION NP_112247

R126H

1 MALNSSAEDG IKRIQDDCPK AGRHSYIFVM IPTLYSIIFV VGIFGNSLVV IVIYFYMKLK
61 TVASVFLNL ALADLCFLT CPLWAVYTAM EYRWPFGNHL CKIASASVTF NLYASVFLT
121 CLSID^HYLAI VHPMKSRLRR TMLVAKVTCI IIWLMAGLAS LPAVIHRNVY FIENTNITVC
181 AFHYESRNST LPIGLGLTKN ILGFLFPFLI ILTSYTLIWK ALKKAYEIQK NKPRNDDIFR
241 IIMAIVLFFF FSWVPHQIFT FLDVLIQLGV IHDCKISDIV DTAMPITICI AYFNNCLNPL
301 FYGFLGKKFK KYFLQLLKYI PPKAKSHSSL STKMSTLSYR PSDNMSSSAK KPASCFEVE
(SEQ ID NO:45)

FIGS. 5A – 5B

A. Amino Acid sequence of the hGPR3- Enhanced Receptor

MMWGAGSPLAWLSAGSGNVNVSSVGPAEGPTGPAAPLPSPKAWDVVLCISGTLVSCENA
LVVAIIIVGTPAFRAPMFLLVGSLAVADLLAGLGLVLHFHFAAVFCIGSAEMSLVLVGVLAM
AFTASIGSLLAITVDRLSLYNALTYSETTVTRTYVMLALVWGGALGLLLPVLAWNC
LDGLTTCGVVYPLSKNHLVLAIAFFMVFGIMLQLYAQICRIVCRHAQQIALQRHLLPA
SHYVATRKGIA TLAVVLGAFAACWLPFTVYCLLGDAHSPPLYTYLTLLPATYNSMINPI
IYAFRNQDVQKVLWAVCCCCAAARGRTPPSLGPQDESCTTASSSLAKDTSS
(SEQ ID No: 46)

B. Nucleotide sequence of the hGPR3- Enhanced Receptor

ATGATGTGGGGTGCAGGCAGCCCTCTGGCCTGGCTCTCAGCTGGCTCAGGCAACGTGAA
TGTAAGCAGCGTGGGCCCAGCAGAGGGGCCCACAGGTCCAGCCGCACCACTGCCCTCGC
CTAAGGCCTGGGATGTGGTGCTCTGCATCTCAGGCACCCTGGTGTCTGCGAGAATGCG
CTAGTGGTGGCCATCATCGTGGGCACTCCTGCCTTCCGTGCCCCCATGTTCTGCTGGT
GGGCAGCCTGGCCGTGGCAGACCTGCTGGCAGGCCTGGGCCTGGTCTGCACTTTGCTG
CTGTCTTCTGCATCGGCTCAGCGGAGATGAGCCTGGTGCTGGTTGGCGTGCTGGCAATG
GCCTTTACYGCCAGCATCGGCAGTCTACTGGCCATCACTGTGCGACCGCTACCTTTCTCT
GTACAATGCCCTCACCTACTATTAGAGACAACAGTGACACGGACCTATGTGATGCTGG
CCTTAGTGTGGGGAGGTGCCCTGGGCCTGGGGCTGCTGCCTGTGCTGGCCTGGAAGTGC
CTGGATGGCCTGACCACATGTGGCGTGGTTTATCCACTCTCCAAGAACCATCTGGTAGT
TCTGGCCATTGCCTTCTTCATGGTGTTTGGCATCATGCTGCAGCTCTACGCCCAAATCT
GCCGCATCGTCTGCCGCCATGCCAGCAGATTGCCCTTCAGCGGCACCTGCTGCCTGCC
TCCCACTATGTGGCCACCCGCAAGGGCATTGCCCACTGGCCGTGGTGCTTGGAGCCTT
TGCCGCCTGCTGGTTGCCCTTCACTGTCTACTGCCTGCTGGGTGATGCCCACTCTCCAC
CTCTCTACACCTATCTTACCTTGCTCCCTGCCACCTACAACCTCCATGATCAACCCTATC
ATCTACGCCTTCCGCAACCAGGATGTGCAGAAAGTGCTGTGGGCTGTCTGCTGCTGCTG
TGCGGGCCGCACGGGGACGCACCCACCCAGCCTGGGTCCCCAAGATGAGTCCTGCACCA
CCGCCAGCTCCTCCCTGGCCAAGGACACTTCATCGTGA
(SEQ ID No: 47)

FIGS. 5C – 5D**C. Amino Acid sequence of the hGPR6- Enhanced Receptor**

MNASAASLND SQVVVAAEGAAAAATAAGGPD TGEWGPPAAAALGAGGGANGSLELSSQ
LSAGPPGLLLPAVNPWDVLLCVSGTVIAGENALVVALIASTPALRTPMFVLVGLATAD
LLAGCGLILHFVFQYLPSETVSLLTVGFLVASFAASVSSLLAITVD RYLSLYNALTYY
SRRTLLGVHLLLAATWTVSLGLGLLPVLGWNCLAERAACSVVRPLARSHVALLSAAFFM
VFGIMLHLYVRICQVVRHAHQIALQQHCLAPPHLAATRKG VGT LAVVLGTFGASWLPF
AIYCVVGSHEDPAVYTYATLLPATYNSMINPIIYAFRNQEIQRALWLLL CGCAAARGRT
PPSLGPQDE SCTTASSSLAKDTSS

(SEQ ID No: 48)

D. Nucleotide sequence of the hGPR6- Enhanced Receptor

ATGAACGCGAGCGCCGCCTCGCTCAACGACTCCCAGGTGGTGGTAGTGCGGCCGAAGG
AGCGGCGGCGGCGGCCACAGCAGCGGGGGCGGACACGGGCGAATGGGGACCCCTG
CTGCGGCGGCTCTAGGAGCCGGCGGCGGAGCTAATGGGTCTCTGGAGCTGTCTCGCAG
CTGTGCGGCTGGGCCACCGGACTCCTGCTGCCAGCGGTGAATCCGTGGGACGTGCTCCT
GTGCGTGTGCGGGACAGTGATCGCTGGAGAAAACGCGCTGGTGGTGGCGCTCATCGCGT
CCACTCCGGCGCTGCGCACGCCCATGTTCTGTGCTGGTAGGCAGCCTGGCCACCGCTGAC
CTGTTGGCGGGCTGTGGCCTCATCTTGCACTTTGTGTTCCAGTACTTGGTGCCCTCGGA
GACTGTGAGTCTGCTCACGGTGGGCTTCCTCGTGGCCTCCTTCGCCGCTCTGTGTCAGCA
GCCTGCTGGCCATTACGGTGGACCGCTACCTGTCCCTGTATAACGCGCTCACCTATTAC
TCGCGCCGGACCTGTGGGCGTGACCTCCTGCTTGCCGCCACTTGGAACCGTGTCCCT
AGGCCTGGGGCTGCTGCCCGTGCTGGGCTGGAACTGCCTGGCAGAGCGCGCCGCTGCA
GCGTGGTGCGCCCGCTGGCGCGCAGCCACGTGGCTCTGCTCTCCGCCGCCTTCTTCATG
GTCTTCGGCATCATGCTGCACCTGTACGTGCGCATCTGCCAGGTGGTCTGGCGCCACGC
GCACCAGATCGCGCTGCAGCAGCACTGCCTGGCGCCACCCCATCTCGCTGCCACCAGAA
AGGGTGTGGGTACACTGGCTGTGGTGTGCTGGGCACTTTCGGCGCCAGCTGGCTGCCCTTC
GCCATCTATTGCGTGGTGGGCGAGCCATGAGGACCCGGCGGTCTACACTTACGCCACCCT
GCTGCCCGCCACCTACAACCTCCATGATCAATCCCATCATCTATGCCTTCCGCAACCAGG
AGATCCAGCGCGCCCTGTGGCTCCTGCTCTGTGGCTGTGCGGCCGCACGGGGACGCACC
CCACCCAGCCTGGGTCCCCAAGATGAGTCCTGCACCACCGCCAGCTCCTCCCTGGCCAA
GGAACTTCATCGTGA

(SEQ ID No: 49)

FIGS. 5E – 5F

E. Amino Acid sequence of the hGPR12- Enhanced Receptor

MNEDLKVNLSGLPRDYLDAAAENISAAVSSRVPAVEPEPELVVNPWDIVLCTSGTLIS
CENAIIVVLIIFHNPSLRAPMFLIGSLALADLLAGIGLITNFVFAYLLQSEATKLVTIG
LIVASFASVCSLLAITVDRYLSLYYALTYHSERTVTFTYVMLVMLWGTSICLGLLPVM
GWNCLRDESTCSVVRPLTKNNAAILSVSFLFMFALMLQLYIQICKIVMRHAHQIALQHH
FLATSHYVTTTRKGVSTLAIILGTFAACWMPFTLYSLIADYTYPSIYTYATLLPATYNSI
INPVIYAFRNQEIQKALCLICCGCAAARGRTPPSLGPQDESCTTASSSLAKDTSS
(SEQ ID No: 50)

F. Nucleotide sequence of the hGPR12- Enhanced Receptor

ATGAATGAAGACCTGAAGGTCAATTTAAGCGGGCTGCCTCGGGATTATTTAGATGCCCGC
TGCTGCGGAGAACATCTCGGCTGCTGTCTCCTCCCGGGTTCCTGCCGTAGAGCCAGAGC
CTGAGCTCGTAGTCAACCCCTGGGACATTGTCTTGTGTACCTCGGGAACCCTCATCTCC
TGTGAAAATGCCATTGTGGTCTTATCATCTTCCACAACCCAGCCTGCGAGCACCCAT
GTTCTGCTAATAGGCAGCCTGGCTCTTGACAGACCTGCTGGCCGGCATTGGACTCATCA
CCAATTTTGTGTTTTGCTTACCTGCTTCAGTCAGAAGCCACCAAGCTGGTCACGATCGGC
CTCATTGTGCGCTCTTTCTCTGCTCTGTCTGCAGCTTGCTGGCTATCACTGTTGACCG
CTACCTCTCACTGTACTACGCTCTGACGTACCATTCGGAGAGGACGGTCACGTTTACCT
ATGTCATGCTCGTCATGCTCTGGGGGACCTCCATCTGCCTGGGGCTGCTGCCCGTCATG
GGCTGGAAGTGCCTCCGAGACGAGTCCACCTGCAGCGTGGTCAGACCGCTCACCAAGAA
CAACGCGGCCATCCTCTCGGTGTCCTTCTCTTCATGTTTGCGCTCATGCTTCAGCTCT
ACATCCAGATCTGTAAGATTGTGATGAGGCACGCCCATCAGATAGCCCTGCAGCACCAC
TTCCTGGCCACGTCGCACTATGTGACCACCCGAAAGGGTCTCCACCCTGGCTATCAT
CCTGGGGACGTTTGCTGCTTGCTGGATGCCTTTCACCCTCTATTCTTGATAGCGGATT
ACACCTACCCCTCCATCTATACCTACGCCACCCTCCTGCCCAGCCACCTACAATTCCATC
ATCAACCCTGTCATATATGCTTTCAGAAACCAAGAGATCCAGAAAGCGCTCTGTCTCAT
TTGCTGCGGCTGCGCGGCCGCACGGGGACGCACCCACCCAGCCTGGGTCCCCAAGATG
AGTCCTGCACCACCGCCAGCTCCTCCCTGGCCAAGGACACTTCATCGTGA
(SEQ ID No: 51)

FIGS. 5G – 5H**G. Amino Acid sequence of the hSREB3- Enhanced Receptor**

MANTTGEPEEVSGALSPPSASAYVKLVLLGLIMCVSLAGNAILSLLVLKERALHKAPYY
FLLDLCLADGIRSAVCFPFVLASVRHGSSWTFSA LSKIVAFMAVLFCFHAAFMLFCIS
VTRYMAIAHHRFYAKRMTLWTCAAVICMAWTL SVAMAFPPVFDVGTYKFIREEDQCIFE
HRYFKANDTLGFMLMLAVLMAATHAVYGKLLLF EYRHRKMKPVQMPAISONWTFHGP
ATGQAAANWIAGFGRGPMPTLLGIRONGHAASRRL LGMDEVKGEKQLGRMFYAITLLF
LLLWSPYIVACYWRVFKACAVPHRYLATAVWMSFAQA AVNPIVCFLLNKDLKKCLRTH
APCAAARGRTPPSLGPQDESCTTASSSLAKDTSS
(SEQ ID No: 52)

H. Nucleotide sequence of the hSREB3- Enhanced Receptor

ATGGCCAACACTACCGGAGAGCCTGAGGAGGTGAGCGGCGCTCTGTCCCCACCGTCCGC
ATCAGCTTATGTGAAGCTGGTACTGCTGGGACTGATTATGTGCGTGAGCCTGGCGGGTA
ACGCCATCTTGTCCCTGCTGGTGCTCAAGGAGCGTGCCCTGCACAAGGCTCCTTACTAC
TTCCTGCTGGACCTGTGCCTGGCCGATGGCATA CGCTCTGCCGTCTGCTTCCCCTTTGT
GCTGGCTTCTGTGCGCCACGGCTCTTCATGGACCTTCAGTGCACTCAGCTGCAAGATTG
TGGCCTTTATGGCCGTGCTCTTTTGCTTCCATGCGGCCTTCATGCTGTTCTGCATCAGC
GTCACCCGCTACATGGCCATCGCCACCAACCGCTTCTACGCCAAGCGCATGACACTCTG
GACATGCGCGGCTGTCTATCTGCATGGCCTGGACCCTGTCTGTGGCCATGGCCTTCCCAC
CTGTCTTTGACGTGGGCACCTACAAGTTTATTTCGGGAGGAGGACCAAGTGATCTTTGAG
CATCGCTACTTCAAGGCCAATGACACGCTGGGCTTCATGCTTATGTTGGCTGTGCTCAT
GGCAGCTACCCATGCTGTCTACGGCAAGCTGCTCCTCTTCGAGTATCGTCACCGCAAGA
TGAAGCCAGTGCAAGATGGTGCCAGCCATCAGCCAGAACTGGACATTCCATGGTCCCGGG
GCCACCGGCCAGGCTGCTGCCAACTGGATCGCCGGCTTTGGCCGTGGGCCCATGCCACC
AACCCTGCTGGGTATCCGGCAGAAATGGGCATGCAGCCAGCCGGCGGCTACTGGGCATGG
ACGAGGTCAAGGGTGAAAAGCAGCTGGGCGCATGTTCTACGCGATCACACTGCTCTTT
CTGCTCCTCTGGTCACCCTACATCGTGGCCTGCTACTGGCGAGTGTGTTGTGAAAGCCTG
TGCTGTGCCCCACCGCTACCTGGCCACTGCTGTTTGGATGAGCTTCGCCCAGGCTGCCG
TCAACCCAATTGTCTGCTTCTGCTCAACAAGGACCTCAAGAAGTGCTGAGGACTCAC
GCCCCCTGCGCGGCCGCACGGGGACGCACCCACCCAGCCTGGGTCCCCAAGATGAGTC
CTGCACCACCGCCAGCTCCTCCCTGGCCAAGGACACTTCATCGTGA
(SEQ ID No: 53)

FIGS. 5I – 5J

I. Amino Acid sequence of the hSREB2- Enhanced Receptor

MANYSHAADNILQNLSP LTAFLKLTSLGFIIGVSVVGNLLISILLVKDKTLHRAPYYFL
LDLCCSDILRSAICFPFVNSVKNGSTWYGTTLTKVIAFLGVLSCFHTAFMLFCISVT
RYLAIAHHRFYTKRLTFWTCLAVICMVWTLVAMAFPPVLDVGTYSFIREEDQCTFQHR
SFRANDSLGFMLLLALILLATQLVYLKLIFFVHDDRKMKPQVFVAAVSQNWTFHGPAS
GQAAANWLAGFGRGPTPPTLLGIRQNANTTGRRRLVLDEFKMEKRISRMFYIMTFLFL
TLWGPYLVACYWRVFARGPVVPGGFLTAAVWMSFAQAGINPFVCIFSNRELRRCFSTTL
LYCAAARGRTPPSLGPQDESCTTASSSLAKDTSS
(SEQ ID No: 54)

J. Nucleotide sequence of the hSREB2- Enhanced Receptor

ATGGCGAACTATAGCCATGCAGCTGACAACATTTTGCAAAATCTCTCGCCTCTAACAGC
CTTTCTGAAACTGACTTCCTTGGGTTTCATAATAGGAGTCAGCGTGGTGGGCAACCTCC
TGATCTCCATTTTGCTAGTGAAAGATAAGACCTTG CATAGAGCACCTTACTACTTCCTG
TTGGATCTTTGCTGTT CAGATATCCTCAGATCTGCAATTTGTTTCCCATTTGTGTTCAA
CTCTGTCAAAAATGGCTCTACCTGGACTTATGGGACTCTGACTTGCAAAGTGATTGCCT
TTCTGGGGGTTTGTCTGTTCCACACTGCTTTCATGCTCTTCTGCATCAGTGTCAAC
AGATACTTAGCTATCGCCCATCACCGCTTCTATACAAAGAGGCTGACCTTTTGGACGTG
TCTGGCTGTGATCTGTATGGTGTGGACTCTGTCTGTGGCCATGGCATTTCCTCCCGGTTT
TAGACGTGGGCACTTACTCATT CATTAGGGAGGAAGATCAATGCACCTTCCAACACCGC
TCCTTCAGGGCTAATGATTCCTTAGGATTTATGCTGCTTCTTGCTCTCATCCTCCTAGC
CACACAGCTTGTCTACCTCAAGCTGATATTTTCGTCCACGATCGAAGAAAAATGAAGC
CAGTCCAGTTTGTAGCAGCAGTCAGCCAGA ACTGGACTTTTCATGGTCCTGGAGCCAGT
GGCCAGGCAGCTGCCAATTGGCTAGCAGGATTTGGAAGGGGTCCCACACCACCCACCTT
GCTGGGCATCAGGCAAAATGCAAACACCACAGGCAGAAGAAGGCTATTGGTCTTAGACG
AGTTCAAAATGGAGAAAAGAATCAGCAGAATGTTCTATATAATGACTTTTCTGTTTCTA
ACCTTGTGGGGCCCTACCTGGTGGCCTGTTATTGGAGAGTTTTTGCAAGAGGGCCTGT
AGTACCAGGGGGATTTCTAACAGCTGCTGTCTGGATGAGTTTTGCCCAAGCAGGAATCA
ATCCTTTTGTCTGCATTTTCTCAAACAGGGAGCTGAGGCGCTGTTTCAGCACAACCCTT
CTTTACTGCGCGGCCGCACGGGGACGCACCCCAACCAGCCTGGGTCCCCAAGATGAGTC
CTGCAACCACCGCCAGCTCCTCCCTGGCCAAGGACACTTCATCGTGA
(SEQ ID No: 55)

FIGS. 5K – 5L

K. Amino Acid sequence of the hGPR8- Enhanced Receptor

MQAAGHPEPLDSRGSFSLPTMGANVSQDNGTGHNATFSEPLPFLYVLLPAVYSGICAVG
LTGNTAVIILVILRAPKMKTVTNVFIILNLAVADGLFTLVLPVNIAEHLLOQYWPFGELLCK
LVLAVDHYNIFSSIIYFLAVMSVDRLVVLATVRSRHMPWRTYRGAKVASLCVWLGVTVL
VLPFFSFAGVYSNELQVPSCGLSFPWPERVWFKASRVYTLVLGFVLPVCTICVLYTDLL
RRLRAVRLRSGAKALGKARRKVTVLVLVVLAVCLLCWTFPHLASVVALTTDLPQTPLVI
SMSYVITSLSYANSCLNPFLYAFLDDNFRKNFRSILRCAAARGRTPPSLGPQDESCCTTA
SSSLAKDTSS

(SEQ ID No: 56)

L. Nucleotide sequence of the hGPR8- Enhanced Receptor

ATGCAGGCCGCTGGGCACCCAGAGCCCCTTGACAGCAGGGGCTCCTTCTCCCTCCCCAC
GATGGGTGCCAACGTCTCTCAGGACAATGGCACTGGCCACAATGCCACCTTCTCCGAGC
CACTGCCGTTCTCTATGTGCTCCTGCCCGCGTGTA TCTCCGGGATCTGTGCTGTGGGG
CTGACTGGCAACACGGCCGTCATCCTTGTAATCCTAAGGGCGCCCAAGATGAAGACGGT
GACCAACGTGTTTATCCTGAACCTGGCCGTCGCCGACGGGCTCTTCACGCTGGTACTGC
CCGTCAACATCGCGGAGCACCTGCTGCAGTACTGGCCCTTCGGGGAGCTGCTCTGCAAG
CTGGTGCTGGCCGTCGACCACTACAACATCTTCTCCAGCATCTACTTCTAGCCGTGAT
GAGCGTGGAACGATACCTGGTGGTGCTGGCCACCGTGAGGTCCCGCCACATGCCCTGGC
GCACCTACCGGGGGGCGAAGGTCGCCAGCCTGTGTGTCTGGCTGGGCGTCACGGTCCTG
GTTCTGCCCTTCTTCTCTTTTCGCTGGCGTCTACAGCAACGAGCTGCAGGTCCCAAGCTG
TGGGCTGAGCTTCCCGTGCGCCGAGCGGGTCTGGTTCAAGGCCAGCCGTGTCTACACTT
TGGTCCTGGGCTTCGTGCTGCCCCTGTGTCACCATCTGTGTGCTCTACACAGACCTCCTG
CGCAGGCTGCGGGCCGTGCGGCTCCGCTCTGGAGCCAAGGCTCTAGGCAAGGCCAGGCG
GAAGGTGACCGTCTTGGTCTCGTGTGCTGGCCGTGTGCCTCCTCTGCTGGACGCCCT
TCCACCTGGCCTCTGTGCTGGCCCTGACCACGGACCTGCCCCAGACCCCACTGGTCATC
AGTATGTCCTACGTATCACCAGCCTCAGCTACGCCAACTCGTGCCTGAACCCCTTCTCT
CTACGCCTTTCTAGATGACAACTTCCGGAAGAACTTCCGCAGCATATTGCGGTGCGCGG
CCGCACGGGGACGCACCCACCCAGCCTGGGTCCCCAAGATGAGTCCTGCACCACCGCC
AGCTCCTCCCTGGCCAAGGACACTTCATCGTGA

(SEQ ID No: 57)

FIGS. 5M – 5N

M. Amino Acid sequence of the hGPR22-Enhanced Receptor

MCFSPILEINMQSESNIIVRDDIDDINTNMYQPLSYPLSFQVSLTGFLMLEIVLGLGSN
LTVLVLYCMKSNLINSVSNIIITMNLHVLDVVICVGCIPLTIVILLLSLESNTALICCFH
EACVSFASVSTAINVFAITLDRYDISVKPANRILTMGRAVLMISIWIFSFFSFLIPFI
EVNFFSLQSGNTWENKTLLCVSTNEYYTELGMYHLLVQIPIFFFTVVVMLITYTKILQ
ALNIRIGTRFSTGQKKKARKKKTISLTQHEATDMSQSSGGRNVVFGVRTSVSVIIALR
RAVKRHRERRERQKRVFRMSLLIISTFLLCWTPISVLNNTTILCLGPSDLLVKLRCLFLV
MAYGTTIFHPLLYAFTRQKFQKVLKSKMKKRVVCAAARGRTPPSLGPQDESCTTASSSL
AKDTSS

(SEQ ID No: 58)

N. Nucleotide sequence of the hGPR22-Enhanced Receptor

ATGTGTTTTTCTCCaTTCTGGAAATCAACATGCAGTCTGAATCTAACATTACAGTGCG
AGATGACATTGATGACATCAACACCAATATGTACCAACCACTATCATATCCGTTAAGCT
TTCAAGTGTCTCTCACCGGATTTCTTATGTTAGAAATTGTGTTGGGACTTGGCAGCAAC
CTCACTGTATTGGTACTTTACTGCATGAAATCCAACCTTAATCAACTCTGTCTAGTAACAT
TATTACAATGAATCTTCATGTACTTGATGTAATAATTTGTGTGGGATGTATTCCTCTAA
CTATAGTTATCCTTCTGCTTTCACTGGAGAGTAACACTGCTCTCATTTGCTGTTTCCAT
GAGGCTTGTGTATCTTTTGCAAGTGTCTCAACAGCAATCAACGTTTTTGCTATCACTTT
GGACAGATATGACATCTCTGTAAACCTGCAAACCGAATTCTGACAATGGGCAGAGCTG
TAATGTTAATGATATCCATTGGATTTTTTCTTTTTTCTCTTTCCTGATTCCTTTTATT
GAGGTAAATTTTTTCACTCTTCAAAGTGGAAATACCTGGGAAAACAAGACACTTTTATG
TGTCAGTACAAATGAATACTACTGAACTGGGAATGTATTATCACCTGTTAGTACAGA
TCCCAATATTCTTTTTCACTGTTGTAGTAATGTTAATCACATACACCAAAATACTTCAG
GCTCTTAATATTGGAATAGGCACAAGATTTTCAACAGGGCAGAAGAAGAAAGCAAGAAA
GAAAAAGACAATTTCTTAACCACACAACATGAGGCTACAGACATGTCACAAAGCAGTG
GTGGGAGAAATGTAGTCTTTGGTGTAAAGAACTTCAGTTTCTGTAATAATTGCCCTCCGG
CGAGCTGTGAAACGACACCGTGAACGACGAGAAAGACAAAAGAGAGTCTTCAGGATGTC
TTTATTGATTATTTCTACATTTCTTCTCTGCTGGACACCAATTTCTGTTTTAAATACCA
CCATTTTATGTTTAGGCCCAAGTGACCTTTTAGTAAATTAAGATTGTGTTTTTTAGTC
ATGGCTTATGGAACAACTATATTTACCCTCTATTATATGCATTCACTAGACAAAATT
TCAAAGGTCTTGAAAAGTAAATGAAAAAGCGAGTTGTTTGTGCGCCGCACGGGGAC
GCACCCACCCAGCCTGGGTCCCCAAGATGAGTCCTGCACCACCGCCAGCTCCTCCCTG
GCCAAGGACACTTCATCGTGA

(SEQ ID No: 59)

FIGS. 6A – 6C

A. Amino acid sequence of the β_2 AR-V2R chimera

MGQPGNGSAFLAPNRSHAPDHDVTQQRDEVWVVGMGIVMSLIVLAIVFGNVLVITAI
 AKFERLQTVTNYFITSLACADLVMGLAVVPFGAAHILMKMWTFGNFWCEFWTSIDVLC
 VTASIELCVIAVDRYFAITSPFKYQSLTGNKARVILMVWIVSGLTSFLPIQMHWYRAT
 HQEAINCYANETCCDFFTQAYALASSIVSFYVPLVIMVFVYSRVFQEAKRQLQKIDKSE
 GRFHVQNLSQVEQDGRGTGHGLRRSSKFCLEHKAALKTLGIIMGTFTLCWLPFFIVNIVHV
 IQDNLIRKEVYILLNWIGYVNSGFNPLIYCRSPDFRIAFQELLCARGRTPPSLGPQDESCTT
 ASSSLAKDTSS

(Seq. ID No. 60)

B. Amino acid sequence of the MOR-V2R chimera

MDSSTGPGNTSDCSDPLAQASCSPAPGSWLNLSHVDGNQSDPCGLNRTGLGGNDSLCP
 QTGSPSMVTAITIMALYSISVCVVGLFGNFLVMYVIVRYTKMKTATNIYIFNLALADALAT
 STLPFQSVNYLMGTWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKALDFR
 TPRNAKIVNVCNWILSSAIGLPVMFMATTKYRQGSIDCTLTFSHPTWYWENLLKICVFIF
 AFIMPILIITVCYGLMILRLKSVRMLSGSKEKDRNLRRITRMVLVVAVFIVCWTPHIYVI
 IKALITIPETTFQTVSWHFCIALGYTNSCLNPVLYAFLDENFKRCFREFCAAARGRTPPSL
 GPQDESCTTASSSLAKDTSS

(Seq. ID No. 61)

C. Amino acid sequence of the D1AR-V2R chimera

MAPNTSTMDEAGLPAERDFSFRILTACFLSLLILSTLLGNTLVCAAVIRFRHLRSKVTNFF
 VISLAVSDLLVAVLVMPWKAVAEIAGFWPFGSFCNIWVAFDIMCSTASILNLCVISVDYR
 WAISSPFQYERKMTPKAAFILISVAWTLVLSIFIPVQLSWHKAKPTWPLDGNFTSLEDTE
 DDNCDTRLRSRTYAISSSLISFYIPVAIMIVTYTTSIYRIAQKQIRRIALERA AVHAKNCQTT
 AGNGNPVECAQSESSFKMSFKRETKVLKTLVIMGVFVCCWLPFFISNCMVFPFCGSEET
 QPFCIDSITFDVFVWFGWANSSLNPIIYAFNADFQKAFSTLLGCYRLCAAARGRTPPSLGP
 QDESCTTASSSLAKDTSS

(Seq. ID No. 62)

FIGS. 6D – 6F

D. Amino acid sequence of the 5HT1AR-V2R chimera

MDVLSPGQGNNNTTSPAPFETGGNTTGISDVTVSQVITSLLLGLTIFCAVLGNACVVAA
 IALERSLQNVANYLIGSLAVTDLMVSVLVLPMAALYQVLNKWTLGQVTCDLFIALDVL
 CCTSSILHLCAALDRYWAITDPIDYVNKRTPRRAAALISLTWLIGFLISIPPMLGWRTPED
 RSDPDACTISKDHGYTIYSTFGAFYIPLLLMLVLYGRIFRAARFRIRKTVKKVEKTGADT
 RHGASPAPQPKKSVNGESGSRNWRLGVESKAGGALCANGAVRQGDDGAALEVIEVHR
 VGNSKEHLPLPSEAGPTPCAPASFERKNERNAEAKRKMALARERKTVKTLGIIMGTFILC
 WLPFFIVALVLPFCESSCHMPTLLGAIINWLGYSNSLLNPVIYAYFNKDFQNAFKKIICKN
 FCAAARGRTPPSLGPQDESCTTASSSLAKDTSS

(Seq. ID No. 63)

E. Amino acid sequence of the β 3AR-V2R chimera

MAPWPHENSSLAPWPDLPNTANTSGLPVPWEAALAGALLALAVLATVGGNLLV
 IVAIAWTPRLQTMNVFVTSLAAADLVMGLLVPPAATLALTGHWPLGATGCELWTSV
 DVLCVTASIELCALAVDRYLAVTNPLRYGALVTKRCARTAVVLVWVVSAAVSFAPIM
 SQWWRVGADAEAQRCHSNPRCCAFASNMPYVLLSSVSFYLPLLVMLFVYARVFVVA
 TRQLRLLRGELGRFPPEESPPAPSRSLAPAPVGTAPPEGVPACGRRPARLLPLREHRALC
 TLGLIMGTFTLCWLPFFLANVLRALGGPSLVPGAFLALNWLGYANSFNPFIYCRSPDF
 RSAFRLLCRCAAARGRTPPSLGPQDESCTTASSSLAKDTSS

(Seq. ID No. 64)

F. Amino acid sequence of the Edg1R-V2R chimera

MGPTSVPLVKAHRSSVSDYVNYDIIVRHNYTGKLNISADKENSILTSVVFILICCFIILE
 NIFVLLTIWKTKKFHRPMYYFIGNLALSDDLAVGTANLLLSGATTYKLTQAQWFLRE
 GSMFVALSASVFSLAIAIERYITMLKMKLHNGSNFRLFLISACWVISLILGGLPIMGW
 NCISALSSCSTVLPYHKHYILFCTTVFTLLLSIVILYCRISLVTRSRRLTFRKNISKAS
 RSSEKSLALLKTVIIVLSVFIACWAPLFILLLLDVGCKVKTCDFRAEYFLVLAVLNSGT
 NPIIYTLTNKEMRRAFIRIMSCCKCAAARGRTPPSLGPQDESCTTASSSLAKDTSS

(Seq. ID No. 65)